Long-term Resveratrol and Metabolism

Maastricht University Medical Centre (MUMC) logo

Maastricht University Medical Centre (MUMC)

Status

Completed

Conditions

Pre-diabetes

Treatments

Dietary Supplement: resveratrol
Dietary Supplement: placebo

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02565979
15-3-037

Details and patient eligibility

About

The main objective of the study is to investigate if 6 months resveratrol supplementation can improve glucose tolerance in overweight/obese individuals. As secondary objectives we want to investigate whether resting energy metabolism, intra-hepatic lipid content, physical performance, body composition and quality of life change by 6 months resveratrol supplementation in these individuals.

Enrollment

42 patients

Sex

All

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men aged 40-70 years and postmenopausal women aged 50-70 years
  • BMI: 27-35 kg/m2
  • Stable dietary habits: no weight gain or loss > 5kg in the last three months
  • Willingness to limit consumption of resveratrol-containing food products and willingness to refrain from using resveratrol containing supplements
  • Subjects will only be included when the dependent medical doctor of this study approves participation after evaluating data obtained during screening

Exclusion criteria

  • Uncontrolled hypertension
  • HbA1c > 6.5%
  • Previously diagnosed with type 2 diabetes
  • Medication use known to interfere with glucose homeostasis/metabolism
  • Current alcohol consumption > 20 grams alcohol/day
  • Subjects who do not want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study.
  • Participation in another biomedical study within 1 month before the start of the intervention
  • Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

42 participants in 2 patient groups, including a placebo group

Resveratrol
Active Comparator group
Description:
resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
Treatment:
Dietary Supplement: resveratrol
Placebo
Placebo Comparator group
Description:
placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
Treatment:
Dietary Supplement: placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems